文献速递医学教育与科研方法流行病学与生物统计

PRISMA harms清单实施前药物系统综述的安全性报告质量较差

The reporting of safety among drug systematic reviews was poor before the implementation of the PRISMA harms checklist.
PubMed 文献 · J Clin Epidemiol · 2018-09-29

该横断面调查纳入2015年发表的120篇药物系统综述(Cochrane与非Cochrane各60篇),用2016年PRISMA harms清单评估安全性报告质量,发现清单23项评分中位数仅4分,Cochrane与非Cochrane无差异,仅1项报告充分,4个核心条目依从率1.7%–9.2%,提示亟需使用该清单规范安全性报告。

要点

  • PRISMA harms清单发布前的药物系统综述安全性报告质量普遍较差。
  • Cochrane与非Cochrane综述在安全性报告评分上无显著差异。
  • 4个核心安全性报告条目依从率仅1.7%–9.2%,亟需规范。

核心结论

  • PRISMA harms清单实施前的Cochrane与非Cochrane药物系统综述安全性信息报告质量均较差。
  • 研究结果提示药物系统综述报告安全性时强烈需要使用PRISMA harms清单。

研究设计与样本

  • 横断面调查,检索PubMed识别2015年发表于Cochrane系统综述数据库或核心临床期刊的系统综述。
  • 按1:1比例随机选取评估药物效果(含疗效与安全性)的Cochrane与非Cochrane系统综述各60篇,共120篇。
  • 使用2016年发表的PRISMA harms清单(23项)评估安全性报告质量,并用多变量线性回归分析6个预设变量与报告完整性的关联。

主要发现

  • PRISMA harms清单23项评分中位数4分(第一、第三四分位数:2,6)。
  • Cochrane与非Cochrane综述评分无差异(4.5[2,7] vs 4[2.5,5];P=0.29)。
  • 仅1项(结论与综述发现一致)报告充分,依从率81.6%;其余条目依从率1.7%–68.3%。
  • PRISMA harms清单4个核心报告条目依从率仅1.7%–9.2%。
  • 多变量线性回归未发现任何研究特征与PRISMA harms报告评分显著关联,可能因评分变异有限。

关键数值与推荐

  • PRISMA harms清单共23项,评分中位数4分(第一、第三四分位数:2,6)。
  • Cochrane综述评分4.5(2,7),非Cochrane综述4(2.5,5),P=0.29。
  • 仅1项条目依从率81.6%,其余条目依从率范围1.7%–68.3%。
  • 4个核心报告条目依从率范围1.7%–9.2%。

临床怎么用

  • 药物系统综述应使用PRISMA harms清单规范安全性信息的报告。
  • 报告安全性时应重点关注PRISMA harms清单的4个核心条目。

局限性

  • 研究仅纳入2015年发表的系统综述,为PRISMA harms清单发布前的现状。
  • 多变量分析因评分变异有限,未发现研究特征与报告质量的显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine, through a cross-sectional survey, how well safety information was reported among drug systematic reviews predating PRISMA harms checklist and explore factors associated with better reporting. STUDY DESIGN AND SETTING: We searched PubMed to identify all systematic reviews published in the Cochrane Database of Systematic Review or the core clinical journals in 2015, one year before the PRISMA harms checklist was published. We randomly selected, in a 1:1 ratio, Cochrane and non-Cochrane systematic reviews assessing drug effects (including both efficacy and safety). We used the PRISMA harms checklist published in 2016 to assess the quality of reporting of drug safety information. Multivariable linear regression analyses were used to explore the association of six prespecified variables with more complete reporting of PRISMA harms items. RESULTS: We included 120 systematic reviews, including 60 Cochrane and 60 non-Cochrane reviews. Scores on the PRISMA harms checklist (23 items) were low (median 4, [first, third quartile: 2, 6]), with no difference between Cochrane and non-Cochrane reviews (4.5 [2, 7] vs. 4 [2.5, 5]; P = 0.29). Among all eligible reviews, only one item (i.e., state conclusions in coherence with the review findings) was reported adequately (proportion of adherence 81.6%); proportion of reporting for other items ranged from 1.7% to 68.3%. The four essential reporting items from PRISMA harms checklist were also poorly complied (proportion of adherence ranged from 1.7% to 9.2%). Multivariable linear regression analyses found no significant associations between any study characteristic and reporting on the PRISMA harms, likely because of limited variability in scores across studies. CONCLUSIONS: The reporting of safety information was poor both for Cochrane and non-Cochrane drug systematic reviews predating PRISMA harms checklist. The findings suggested a strong need to use the PRISMA harms checklist for reporting safety among drug systematic reviews.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Li L, Xu C, Deng K, et al. The reporting of safety among drug systematic reviews was poor before the implementation of the PRISMA harms checklist. J Clin Epidemiol. 2018. PMID: 30278212. doi:10.1016/j.jclinepi.2018.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。